samedi 8 août 2020


Gamma Medica and Henry Ford Cancer Institute Announce the Availability of LumaGEM® Molecular Breast Imaging (MBI) Machine

Par Rédaction , dans Communiqués , le 19 mai 2017

Tuesday, May 16th 2017 at 1:00pm UTC

The first MBI machine in Michigan specifically designed for women
with dense breast tissue and those that have a higher risk of breast
cancer

WEST BLOOMFIELD, Mich. & SALEM, N.H.–(BUSINESS WIRE)– Gamma
Medica
, a leader in molecular breast imaging (MBI) technology, today
announced that the Henry
Ford Cancer Institute 
has installed Gamma Medica’s LumaGEM®
Molecular Breast Imaging 
system, which is the first MBI machine
in Michigan. MBI is a proven,
effective supplementary screening method to standard mammography and/or
tomosynthesis (3D mammography), significantly increasing early detection
of breast cancer in women.1 The new system can be found at
the Henry Ford West Bloomfield Hospital where it will provide diagnostic
and secondary screenings to women who have a higher risk of breast
cancer and with dense breast tissue.

Approximately 50 percent of U.S. women are reported to have dense breast
tissue. Unfortunately, many do not realize that they have dense tissue,
or the implications dense breast tissue has on increasing their lifetime
risk of breast cancer.2 Additionally, both dense breast
tissue and cancer appear white on mammograms, making it difficult to
distinguish between the two. It’s like trying to find a snowflake in a
snowstorm, which can lead to false negatives or delayed diagnoses.3

“The new installation of the LumaGEM MBI system at the Henry Ford Cancer
Institute gives women in Michigan and surrounding areas access to a
clinically superior diagnostic and secondary breast screening method,”
said Philip Croxford, president and CEO of Gamma Medica. “We are
delighted to be able to partner with the Henry Ford Cancer Institute and
look forward to collaborating with them to help improve early cancer
detection for women who are at greater risk. We believe MBI will ensure
that more women have the opportunity to receive personalized breast
screenings and improved clinical outcomes.”

A prospective
study
conducted by the Mayo Clinic in Rochester, MN found that the
addition of MBI to mammography significantly increased the detection of
breast cancer in women with dense breast tissue.4 The
following year, a retrospective
clinical study
published in the American Journal of Roentgenology’s
August 2016 issue confirmed these findings. This study involved nearly
1,700 women with dense breast tissue over a three year period and found
that LumaGEM had an incremental cancer detection rate of 7.7 cancers per
thousand (7.7/1000) over mammography (which detects 3.0/1000 alone).
Approximately 85 percent of the cancers found in the study were
confirmed to be invasive, of which 82 percent were node negative,
indicating they were detected at an early stage and therefore presented
a better prognosis.5 Clinical research also showcases that
the use of LumaGEM reduces biopsies, often painful and costly, by 50
percent, compared to other modalities.6 The MBI procedure
requires minimal breast compression; patients are able to sit
comfortably throughout the exam and results are typically available the
same day.

“The Henry Ford Cancer Institute offers some of the most advanced
screening options available to our patients, and this technology brings
added imaging capability for women with dense breast tissue,” says
Patricia Miller, M.D., director of Breast Imaging at Henry Ford West
Bloomfield Hospital.

The new technology was made possible by philanthropic support and
donations.

About Gamma Medica, Inc.
Gamma Medica, Inc. is a women’s
health company focused on overcoming the limitations of anatomical
imaging experienced by mammography and other screening modalities in the
early detection of breast cancer. The company’s LumaGEM® MBI system is
the first commercially available, FDA-cleared, fully solid-state digital
imaging system utilizing dual-head Digital Direct Conversion Gamma
Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90
percent sensitivity and specificity, LumaGEM MBI has been shown to
significantly improve cancer detection in women with dense breast tissue
with fewer false positives relative to anatomical imaging technologies,
such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com.

About the Henry Ford Cancer Institute
The Henry Ford Cancer
Institute is one of the largest cancer programs in Michigan, providing
care at four hospitals and four outpatient facilities throughout
southeast Michigan. Treatment for the most complex or rare cancers and
the Institute’s extensive cancer research program is anchored by Henry
Ford Hospital. For more information, visit www.henryford.com/cancer.

1 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB:
Molecular Breast Imaging at Reduced Radiation Dose for Supplemental
Screening in Mammographically Dense Breasts. American Journal of
Roentgenology. 2015;204(2):241-251.
2 Mandelson MT, et
al. J Natl Cancer Inst. 2000; 92: 1081-7
3 Mayo Clinic.
Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2
4
Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast
Imaging at Reduced Radiation Dose for Supplemental Screening in
Mammographically Dense Breasts. American Journal of Roentgenology.
2015;204(2):241-251.
5 Shermis, RB, Wilson, K, et al.
Supplemental Breast Cancer Screening With Molecular Breast Imaging for
Women With Dense Breast Tissue. American Journal of Roentgenology.
August 2016.
6 Rhodes DJ, Hruska CB, Conners AL, et al.
JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for
Supplemental Screening in Mammographically Dense Breasts. American
Journal of Roentgenology. 2015;204(2):241-251.

Contacts

Racepoint Global
Alexandra Connelly, 1-617-624-3219
gammamedica@racepointglobal.com

Source: Gamma Medica

Étiquettes : , , , , , , , , ,